



CORPORATE PRESENTATION

CSE: PILL | OTCQB: CTABF | FSE:TBF1

DISCLAIMER



This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks related to market and financing conditions as well as risks associated with the industries in which the Company operates, changes in project parameters as plans continue to be refined as well as other risk factors. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information contained herein.

WHAT WE DO



Canntab Therapeutics is **the industry leader in solid oral dose formulations of cannabis** with a product line of cannabinoid (THC & CBD) and terpenoid blends in exacting dosages.

With **one US Patent granted** on September 17th of this year, and **8 more patents pending** in Canada and the United States, we are well positioned to dominate the medical cannabis market with a range of hard pill cannabinoid formulations that provide doctors and patients with a medical grade solution not currently available.



WHAT'S HAPPENING NOW



- We received our **Cannabis Licence**, (Processing - Standard, Federal Sales - Medical).
- We **cleared the 60 days notice period** after submitting our Notice of New Cannabis Product.
- Full scale **hard pill manufacturing has begun** at our facility in Markham, Ontario.
- We received a **US Patent No. 10,772,837** for “Modified Release Multi-Layer Tablet Cannabinoid Formulations” indicating that our formulations are patentable.
- Q1 2021 release of our **new online platform and online store**, to include a telehealth department that will facilitate registration and customer care throughout the purchase process.
- Clinical trial with Dr. Garbuz at UBC to **investigate potentially opioid sparing CBD/THC formulations** in 2021, as we work towards acquiring Drug Identification Numbers (DINs).

STRONG IP PORTFOLIO



1 US patent granted, with 8 more patents pending in the United States and Canada covering our **proprietary processes** and **hard pill formulations** for,

- **Extended Release**
- **Sustained Release**
- **Instant Release**
- **Modified-Release Multi-Layer**
(US Patent Granted)
- **Flash-Melt / Oral Dissolvable Tablet**
- **Bi-Layered**



In August 2019, the Geneva-based International Preliminary Report on Patentability (“IPRP”) indicated a positive finding of patentability for our **Instant Release** Cannabidiol formulation, meaning that, in their opinion, Canntab’s formulation is not only **patentable** but also **novel, non-obvious** and **useful**.

INTELLECTUAL PROPERTY CREATES VALUE FOR SHAREHOLDERS BY PROTECTING MARGINS.

PROPRIETARY PROCESS

Our patent pending proprietary processes allows us to create hard pill formulations that starts with cannabis oil in water emulsions, a unique process in the industry to date.

Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing >> coating



**OUR INNOVATIVE PROCESS CREATES A HARD PILL THAT IS UNIQUE
IN AN INDUSTRY FLOODED WITH OIL FILLED GEL CAPSULES.**

MEETING MEDICAL STANDARDS

Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution.


	CANNTAB Hard Pills	Flower	Oils	Gel Capsules	Edibles
Uniform Dosage	✓	✗	✗	✗	✗
Extended Release Option	✓	✗	✗	✗	✗
Safe Delivery	✓	✗	✗	✓	✗
Discreet	✓	✗	✗	✓	✓
Shelf Life	✓	✗	✗	✗	✗
Bioavailability	●	◐	◑	◐	◐

THERAPEUTIC WINDOW

Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop.

Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief.

Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patient into the **therapeutic window** and maintains that dosage.



CANNTAB'S XR HARD PILL SOLUTION KEEPS PATIENTS IN THE THERAPEUTIC WINDOW, MAINTAINING SYMPTOM RELIEF WHILE AVOIDING NEGATIVE SIDE EFFECTS.

HOW WE GENERATE REVENUE



LICENSING



HARD PILL
PRODUCT SALES
Q4 2020



MANUFACTURING
PROFIT Q4 2020



ONLINE STORE
SALES
Q1 2021


APPROACHING THE OPIOID CRISIS



The opioid crisis **claimed 4,588 Canadians in 2018**. That's approximately 1 life lost every 2 hours¹. Almost 2 million people filled over **9 million prescriptions for opioids in Ontario**, in 2015/2016².

Canntab will conduct a clinical study in 2021 with leading orthopedic surgeon **Dr. Donald Garbuz** at the University of British Columbia. The study aims to show the **potential for reduction of the use of opiates** in post-operative pain care using an **advanced bi-layer extended release formulation** with high CBD and low THC.

Our goal is to gain a **Cannabis Drug License**, with clinical support, and then Drug Identification Numbers (DINs) for our products.



OUR OVERALL STRATEGY IS TO PROVIDE HEALTH CANADA AND THE MEDICAL COMMUNITY WITH AN EFFICACIOUS MEDICATION IN AN OPTIMAL DELIVERY SYSTEM

¹<https://health-infobase.canada.ca/datalab/national-surveillance-opioid-mortality.html>
²<http://opioidprescribing.hqontario.ca/>

TABLET ECONOMICS

Illustrative Gross Margin Sensitivity Analysis

100K Customers Worldwide, 2 pills/day	Low	Base	High
Gross Margin per Pill	\$0.50	\$0.75	\$1.00
Annual Margin per Customer	<u>\$365</u>	<u>\$548</u>	<u>\$730</u>
Annual Gross Margin	\$36.5 MM	\$54.8 MM	\$73 MM

100K Customers Worldwide, 3 pills/day	Low	Base	High
Gross Margin per Pill	\$0.50	\$0.75	\$1.00
Annual Margin per Customer	<u>\$547</u>	<u>\$821</u>	<u>\$1095</u>
Annual Gross Margin	\$ 54.7MM	\$82.1 MM	\$109.5 MM

Note: Sensitivity Analysis is meant to be illustrative and is not intended to be used as a forecast.

CAPITALIZATION

Capitalization Table	Shares	Price	Dollars Raised	
Founders	9,396,000			
Founding Seed Investors	3,804,000			
Jan. 2017 Private Placement	5,652,000	\$ 0.25	\$	1,413,000
Dec. 2017 Private Placement	5,007,656	\$ 1.00	\$	5,007,656
Mar. 2020 Private Placement	7,451,000	\$ 0.50	\$	3,725,500
RTO Shares Issued	625,045			
Exercised Options & Warrants	821,900	Various	\$	221,900
Total Shares Outstanding	32,757,601		\$	10,368,056
	Shares	Price	Maturity Date	Proceeds if Exercised
Original Board Warrants	1,480,000	\$ 0.25	Feb-22	\$370,000
Employee & Consultant Options	1,825,000	\$ 0.60	Mar-22	\$1,095,000
Total Unit Warrants	7,451,000	\$ 0.75	Mar-22	\$5,588,250
Broker Warrants	332,290	\$ 0.50	Sep-21	\$166,145
Special Warrants	262,500	\$ 1.02	Sep-21	\$267,750
F.D. Shares Outstanding	44,108,391			\$7,487,145

MAINTAINING ZERO DEBT AND ONLY 30 DAYS OF TRADE PAYABLES

LOOKING AT THE FUTURE



- **Clinical trial with Dr. Garbuz at UBC** to investigate potentially opioid sparing CBD/THC formulations in 2021, as we work towards acquiring Drug Identification Numbers (DINs).
- Q1 2021 release of our **new online platform and online store**, to include a telehealth department that will facilitate registration and customer care throughout the purchase process.
- Further Clinical trials using our patent pending delivery mechanism and formulation capabilities for **Sleep, Pain, Arthritis, Irritable Bowel Syndrome, and Tempomandibular Joint Disorder**.
- **Partnering** with anyone that wants to use **Canntab's proprietary oral dose delivery system** for their own formulations. Our methodology is the optimal and most cost-effective form for **pharmaceutical medicines**.

MANAGEMENT TEAM



Jeff Renwick, Co-Founder *President & Head of Production*

- Former President/CEO of Orbus Pharma
- Business Development for Indukern Chemie AG
- Extensive experience in drug formulation and business development

Richard Goldstein, Co-Founder *Chief Financial Officer*

- Founder First Republic Capital, Co-Founder Fraser McKenzie, former EVP/Head of IB at Standard Securities
- 28 years of capital markets experience
- MBA in Finance from McMaster University

Larry Latowsky *Chief Executive Officer*

- Former President and CEO of Drug Trading
- Former President and CEO of Katz Group Canada.
- Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board.

Laxaminarayan Joshi *Chief Science Officer*

- Over 20 years of experience in pharmaceuticals
- Previously was Director of R&D for Orbus Pharma Inc.
- An expert in the formulation of cannabinoids.

CONTACT US



Richard Goldstein

Chief Financial Officer

(647) 209-3279

Richard@Canntab.ca

Larry Latowsky

Chief Executive Officer

(416) 458-6491

Larry@Canntab.ca